China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
BHP Shares Fall as Jansen Potash Project Costs Surge 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
Novo Nordisk (NYSE:NVO) forecasted slower sales growth for 2025, reflecting an expected moderation in demand for its blockbuster obesity drug, Wegovy. The Danish pharmaceutical giant projects local currency sales growth between 16% and 24%, down from 26% in 2024 but aligning with analysts' expectations of around 20%.
Novo Nordisk faces increasing competition from Eli Lilly (NYSE:LLY), a key rival in the weight-loss drug market. Despite this, the company reported strong fourth-quarter results, with operating profit surging 37% to 36.7 billion Danish crowns ($5.12 billion), surpassing analysts' estimates of 33.6 billion. For 2025, the company expects operating profit growth between 19% and 27%, compared to last year's 26%.
Wegovy sales more than doubled in Q4, reaching 19.9 billion crowns, up from 9.6 billion a year earlier and exceeding the 17.3 billion recorded in Q3. The sustained demand underscores the drug’s strong market position, although future growth is expected to decelerate.
As the weight-loss drug market evolves, Novo Nordisk continues to navigate supply constraints and rising competition. Investors remain focused on the company’s long-term outlook as it balances expansion efforts with growing market challenges.
